{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:57:08Z","timestamp":1781665028014,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["733273"],"award-info":[{"award-number":["733273"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.vaccine.2025.127897","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:40:30Z","timestamp":1762033230000},"page":"127897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21\/MM"],"prefix":"10.1016","volume":"68","author":[{"given":"Ekta S.","family":"Mukhopadhyay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan G.","family":"Bellamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halidou","family":"Tinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mainga","family":"Hamaluba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Truby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Salman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian V.S.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2025.127897_bb0005","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrd3012","article-title":"Carbohydrate vaccines: developing sweet solutions to sticky situations?","volume":"9","author":"Astronomo","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2025.127897_bb0010","first-page":"129","article-title":"Targeting Glycans on human pathogens for vaccine design","volume":"428","author":"Krumm","year":"2020","journal-title":"Curr Top Microbiol Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127897_bb0015","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4049\/jimmunol.65.5.535","article-title":"Persistence of antibodies in human subjects injected with pneumococcal polysaccharides","volume":"65","author":"Heidelberger","year":"1950","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127897_bb0020","article-title":"Human natural antibodies to mammalian carbohydrate antigens as unsung heroes protecting against past, present, and future viral infections","volume":"9","author":"Galili","year":"2020","journal-title":"Antibodies (Basel)"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127897_bb0025","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127897_bb0030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nri2494","article-title":"Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines","volume":"9","author":"Pollard","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127897_bb0035","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0022-3476(89)80611-0","article-title":"Protective levels of serum antibodies stimulated in infants by two injections of Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugate","volume":"114","author":"Claesson","year":"1989","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2025.127897_bb0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.coviro.2015.02.002","article-title":"Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design","volume":"11","author":"Crispin","year":"2015","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2025.127897_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2017.00248","article-title":"Parasite carbohydrate vaccines","volume":"7","author":"Jaurigue","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127897_bb0050","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0300-9084(01)01294-9","article-title":"The \u03b1-gal epitope (Gal\u03b11-3Gal\u03b21-4GlcNAc-R) in xenotransplantation","volume":"83","author":"Galili","year":"2001","journal-title":"Biochimie"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127897_bb0055","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1021\/acscentsci.7b00517","article-title":"Immunity to \u03b1-gal: toward a single-antigen Pan-vaccine to control major infectious diseases","volume":"3","author":"Cabezas-Cruz","year":"2017","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.vaccine.2025.127897_bb0060","doi-asserted-by":"crossref","unstructured":"Macher BA, Galili U. The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochim Biophys Acta 2008;1780(2):75\u201388.","DOI":"10.1016\/j.bbagen.2007.11.003"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127897_bb0065","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.pt.2015.06.016","article-title":"Regulation of the immune response to \u03b1-gal and vector-borne diseases","volume":"31","author":"Cabezas-Cruz","year":"2015","journal-title":"Trends Parasitol"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127897_bb0070","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1128\/iai.56.7.1730-1737.1988","article-title":"Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora","volume":"56","author":"Galili","year":"1988","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127897_bb0075","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0165-2478(88)90133-2","article-title":"Naturally-occurring anti-alpha-galactosyl antibodies in human Plasmodium falciparum infections--a possible role for autoantibodies in malaria","volume":"19","author":"Ravindran","year":"1988","journal-title":"Immunol Lett"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127897_bb0080","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1038\/s41598-018-28325-w","article-title":"Antibody responses to \u03b1-gal in African children vary with age and site and are associated with malaria protection","volume":"8","author":"Aguilar","year":"2018","journal-title":"Sci Rep"},{"issue":"1733","key":"10.1016\/j.vaccine.2025.127897_bb0085","article-title":"Immunity to \u03b1-gal: the opportunity for malaria and tuberculosis control","volume":"8","author":"Cabezas-Cruz","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127897_bb0090","doi-asserted-by":"crossref","DOI":"10.1590\/0074-02760190145","article-title":"Preliminary assessment of anti-\u03b1-gal IgG and IgM levels in patients with patent plasmodium vivax infection","volume":"114","author":"Coelho","year":"2019","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"17","key":"10.1016\/j.vaccine.2025.127897_bb0095","doi-asserted-by":"crossref","first-page":"9131","DOI":"10.1128\/JVI.00647-07","article-title":"Immunogenicity of Influenza Virus Vaccine Is Increased by Anti-Gal-Mediated Targeting to Antigen-Presenting Cells","volume":"81","author":"Abdel-Motal","year":"2007","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127897_bb0100","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12935-019-1059-8","article-title":"AGI-134: a fully synthetic \u03b1-gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models","volume":"19","author":"Shaw","year":"2019","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127897_bb0105","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1186\/s12885-015-1973-7","article-title":"Epithelial ovarian cancer stem-like cells expressing \u03b1-gal epitopes increase the immunogenicity of tumor associated antigens","volume":"15","author":"Yao","year":"2015","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127897_bb0110","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1021\/acscentsci.7b00311","article-title":"Virus-like particle display of the \u03b1-gal carbohydrate for vaccination against Leishmania infection","volume":"3","author":"Moura","year":"2017","journal-title":"ACS Central Science"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127897_bb0115","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nm.3424","article-title":"Host-cell sensors for plasmodium activate innate immunity against liver-stage infection","volume":"20","author":"Liehl","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2025.127897_bb0120","article-title":"A prophylactic \u03b1-gal-based glycovaccine effectively protects against murine acute Chagas disease","volume":"4(1):13","author":"Portillo","year":"2019","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2025.127897_bb0125","series-title":"WHO prequalifies a second malaria vaccine, a significant milestone in prevention of the disease","author":"WHO","year":"2023"},{"key":"10.1016\/j.vaccine.2025.127897_bb0135","series-title":"Guideline on adjuvnats in vaccines","year":"2004"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127897_bb0140","article-title":"Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens","volume":"10","author":"Trieu","year":"2011","journal-title":"Molecular Cellular Proteomics\u202f: MCP"},{"key":"10.1016\/j.vaccine.2025.127897_bb0145","doi-asserted-by":"crossref","first-page":"46621","DOI":"10.1038\/srep46621","article-title":"Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine","volume":"7","author":"Collins","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.127897_bb0150","series-title":"The natural anti-gal antibody as foe turned friend in medicine: ScienceDirect","author":"Galili","year":"2018"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127897_bb0155","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11882-019-0835-9","article-title":"Role and mechanism of galactose-Alpha-1,3-galactose in the elicitation of delayed anaphylactic reactions to red meat","volume":"19","author":"Hilger","year":"2019","journal-title":"Curr Allergy Asthma Rep"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127897_bb0160","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jaci.2022.02.030","article-title":"\u03b1-Gal present on both glycolipids and glycoproteins contributes to immune response in meat-allergic patients","volume":"150","author":"Chakrapani","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127897_bb0165","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.cell.2014.10.053","article-title":"Gut microbiota elicits a protective immune response against malaria transmission","volume":"159","author":"Yilmaz","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.127897_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2021.100103","article-title":"Overview of vaccine adjuvants","volume":"11","author":"Wu","year":"2021","journal-title":"Medicine in Drug Discovery"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127897_bb0175","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s40264-015-0350-4","article-title":"Comparative safety of vaccine adjuvants: a summary of current evidence and future needs","volume":"38","author":"Petrovsky","year":"2015","journal-title":"Drug Saf"},{"issue":"16","key":"10.1016\/j.vaccine.2025.127897_bb0180","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.vaccine.2016.02.033","article-title":"Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola\/Makona virus glycoprotein (GP) nanoparticle vaccine in mice","volume":"34","author":"Bengtsson","year":"2016","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127897_bb0185","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12026-018-8991-x","article-title":"Matrix-M\u2122 adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice","volume":"66","author":"Magnusson","year":"2018","journal-title":"Immunol Res"},{"key":"10.1016\/j.vaccine.2025.127897_bb0190","first-page":"3","article-title":"Biodistribution of the saponin-based adjuvant matrix-M\u2122 following intramuscular injection in mice. Frontiers","author":"Carnrot","year":"2023","journal-title":"Drug Deliv"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127897_bb0195","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1586\/14760584.1.1.111","article-title":"Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines","volume":"1","author":"Aucouturier","year":"2002","journal-title":"Expert Rev Vaccines"}],"updated-by":[{"DOI":"10.1016\/j.vaccine.2025.127973","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000}}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25011946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25011946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:29:58Z","timestamp":1781663398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25011946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":38,"alternative-id":["S0264410X25011946"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127897","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21\/MM","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127897"}}